{'question': 'Should PCT be used in the ED to guide the initiation of antibiotics for patients with suspected LRTI who are likely to be admitted to the hospital?', 'answer': 'Yes, based on a weak recommendation and moderate certainty of evidence.', 'context': 'We suggest the use of PCT in the ED to guide the initiation of antibiotics for patients with suspected LRTI who are likely to be admitted to the hospital (weak recommendation for use, moderate certainty of evidence)'}
{'question': 'What is the recommended treatment for patients with acute exacerbation of asthma who are likely to be admitted to the hospital?', 'answer': 'PCT (Procalcitonin) may be used in the ED to guide the initiation of antibiotics.', 'context': 'We suggest the use of PCT in the ED to guide the initiation ofantibiotics for patients with acute exacerbation of asthma whoare likely to be admitted to the hospital (weak recommendationfor use, low certainty of evidence)'}
{'question': 'Should PCT be used in the ED to guide the initiation of antibiotics for patients with AECOPD who are likely to be admitted to the hospital?', 'answer': 'Yes, as a weak recommendation with moderate certainty of evidence.', 'context': 'We suggest the use of PCT in the ED to guide the initiation ofantibiotics for patients with AECOPD who are likely to beadmitted to the hospital (weak recommendation for use, moderate certainty of evidence)'}
{'question': 'Should PCT be used in the ED to guide the initiation of antibiotics for patients with dyspnea and suspected or known heart disease who are likely to be admitted to the hospital?', 'answer': 'We suggest against the use of PCT.', 'context': 'We suggest against the use of PCT in the ED to guide the initiation of antibiotics for patients with dyspnea and suspected or known heart disease who are likely to be admitted to the hospital (weak recommendation against use, low certainty of evidence)'}
{'question': 'In patients presenting to the ED with suspected infection, should PCT be used as a guide for initiating antibiotics?', 'answer': 'No, the use of PCT is not recommended due to a weak recommendation against its use based on very low certainty of evidence.', 'context': 'We suggest against the use of PCT based on the criterion of feveralone in patients in the ED to guide the initiation of antibiotics (weak recommendation against use, very low certainty of evidence)'}
{'question': 'Should CRP be used to guide the initiation of antibiotics for patients with respiratory tract infections in the ED?', 'answer': 'No, the use of CRP is not recommended due to a weak recommendation against its use and very low certainty of evidence.', 'context': 'We suggest against the use of CRP in the ED to guide the initiation of antibiotics for patients with respiratory tract infections (weak recommendation against use, very low certainty of evidence)'}
{'question': 'Should rapid NAATs or rapid antigen tests be used for influenza diagnosis in the emergency department?', 'answer': 'No, due to weak recommendations against their use and low certainty of evidence, suggesting they may not provide clinically significant benefits to guide antibiotic therapy.', 'context': 'We suggest against the use of rapid NAATs or rapid antigen tests for influenza to reduce the initiation of antibiotics in the ED (weak recommendation against use, low certainty of evidence)'}
{'question': 'Should mPCR be used to diagnose respiratory pathogens in the emergency department?', 'answer': 'There is a weak recommendation against its use, based on low certainty of evidence.', 'context': 'We suggest against the use of mPCR for respiratory pathogens to reduce the initiation of antibiotics in the ED (weak recommendation against use, low certainty of evidence)'}
{'question': 'Should urinary antigen testing for Streptococcus pneumoniae be used routinely in patients with Lower Respiratory Tract Infection (LRTI) in the Emergency Department (ED)?', 'answer': 'No, due to a weak recommendation against its use and very low certainty of evidence.', 'context': 'We suggest against the routine use of urinary antigen testing for Streptococcus pneumoniae in patients with LRTI in the ED (weak recommendation against use, very low certainty of evidence)'}
{'question': 'Should urinary antigen testing for Legionella pneumophila be used routinely in patients with Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED)?', 'answer': 'No, due to a weak recommendation against its use, as there is very low certainty of evidence.', 'context': 'We suggest against the routine use of urinary antigen testing for Legionella pneumophila in patients with LRTI in the ED (weakrecommendation against use, very low certainty of evidence)'}
{'question': 'In patients with Lower Respiratory Tract Infection (LRTI) in the Emergency Department (ED), when should urinary antigen testing for Legionella pneumophila be considered?', 'answer': 'Urinary antigen testing for Legionella pneumophila is suggested for use in patients with suspected legionellosis or in outbreak settings to guide the use of narrow-spectrum antibiotic therapy.', 'context': 'We suggest the use of urinary antigen testing for Legionella pneumophila in patients with LRTI in the ED with suspected legionellosis or in outbreak settings to guide the use of narrowspectrum antibiotic therapy (good practice statement for use, expert opinion)'}
{'question': 'Should methicillin-resistant Staphylococcus aureus (MRSA) PCR be used to guide antibiotic therapy for purulent skin and soft tissue infections (SSTIs) in the Emergency Department (ED)?', 'answer': 'Yes, but with a weak recommendation due to the high prevalence of community-acquired MRSA, use is suggested.', 'context': 'We suggest methicillin-resistant Staphylococcus aureus (MRSA) PCR for purulent SSTIs in the ED to guide antibiotic therapy in setting with high prevalence of community acquiredMRSA (weak recommendation for use, very low certainty of evidence)'}
{'question': 'Should blood cultures be obtained routinely in patients presenting to the ED with non-severe Community-Acquired Pneumonia (CAP)?', 'answer': 'No, it is not recommended due to a weak recommendation against its use and low certainty of evidence.', 'context': 'We suggest against obtaining blood cultures routinely in patients presenting to the ED with diagnosis of non-severe CAP (weak recommendation against use, low certainty of evidence)'}
{'question': 'In patients admitted with severe Community-Acquired Pneumonia (CAP), should blood cultures be obtained?', 'answer': 'Yes, blood cultures should be obtained in patients with a Pneumonia Severity Index score IV or V or those who require intensive care unit admission.', 'context': 'We suggest obtaining blood cultures in patients admitted with severe CAP, e.g. patients with Pneumonia Severity Index score IV or V or with indications for intensive care unit admission (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained in patients admitted with Community-Acquired Pneumonia (CAP) who have risk factors for unusual or resistant pathogens?', 'answer': 'Yes, according to good practice statement for use and expert opinion, obtaining blood cultures is recommended in such patients.', 'context': 'We suggest obtaining blood cultures in patients admitted with CAP and risk factors for unusual or resistant pathogens (Such as previous infection or colonization with unusual or resistant pathogens, advanced structural lung disease, recent travel to areas with unusual or resistant pathogens or recent hospitalization and systemic antibiotics) (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained routinely in patients presenting to the ED with UTI and systemic symptoms?', 'answer': 'No, according to the current clinical guidelines, it is recommended against obtaining blood cultures routinely in these patients due to weak evidence.', 'context': 'We suggest against obtaining blood cultures routinely in patients presenting to the ED with UTI with systemic symptoms without anatomical abnormalities of the urinary tract in whom a good-quality urine sample for culture is available (weak recommendation against use, very low certainty of evidence)'}
{'question': 'Should blood cultures be obtained in patients presenting to the ED with UTI who have systemic symptoms and received antibiotic pretreatment?', 'answer': 'Yes, it is a good practice to obtain blood cultures in these patients.', 'context': 'We suggest obtaining blood cultures in patients presenting to the ED with UTI with systemic symptoms and antibiotic pretreatment (good practice statement for use, expert opinion)'}
{'question': 'In patients presenting to the ED with a chronic indwelling catheter and UTI with systemic symptoms, should blood cultures be obtained?', 'answer': 'Yes, obtaining blood cultures is recommended as good practice.', 'context': 'We suggest obtaining blood cultures in patients presenting to the ED with a chronic indwelling catheter and UTI with systemic symptoms (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained in immunocompromised patients presenting to the ED with UTI and systemic symptoms?', 'answer': 'Yes, obtaining blood cultures is recommended for use, as suggested by good practice statements.', 'context': 'We suggest obtaining blood cultures in immunocompromised patients presenting to the ED with UTI with systemic symptoms (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained routinely for patients presenting to the ED with cellulitis/erysipelas?', 'answer': 'No, due to a weak recommendation against use and very low certainty of evidence.', 'context': 'We suggest against routinely obtaining blood cultures in patients presenting to the ED with cellulitis/erysipelas (weak recommendation against use, very low certainty of evidence)'}
{'question': 'What is the recommended course of action for immunocompromised patients presenting to the ED with cellulitis/erysipelas?', 'answer': 'Obtaining blood cultures', 'context': 'We suggest obtaining blood cultures in immunocompromised patients presenting to the ED with cellulitis/erysipelas (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained in patients presenting to the ED with cellulitis/erysipelas in situations associated with high risk of non-standard pathogens?', 'answer': 'Yes, as suggested by good practice statements and expert opinion, obtaining blood cultures is recommended for patients with these conditions in high-risk clinical scenarios.', 'context': 'We suggest obtaining blood cultures in patients presenting to the ED with cellulitis/erysipelas in clinical situations associated with high risk of non-standard pathogens (For example, immersion injuries and animal bites) (good practice statement for use, expert opinion)'}
{'question': 'Should blood cultures be obtained in patients presenting to the ED with cellulitis/erysipelas who have an intravascular prosthesis?', 'answer': 'Yes, according to good practice statement for use and expert opinion.', 'context': 'We suggest obtaining blood cultures in patients presenting to the ED with cellulitis/erysipelas who have an intravascular prosthesis, a pacemaker or a valvular prosthesis (good practice statement for use, expert opinion)'}
{'question': 'Should antibiotics be administered to patients presenting to the ED with LRTI without clinical suspicion of pneumonia?', 'answer': 'Yes, withhold antibiotics in patients presenting to the ED with LRTI and no clinical suspicion of pneumonia.', 'context': 'We recommend withholding antibiotics in patients presenting to the ED with LRTI and no clinical suspicion of pneumonia (strong recommendation for use, moderate certainty of evidence)'}
{'question': 'What instructions should be given to patients with LRTI who are discharged from the ED without antibiotics?', 'answer': 'Clear instructions on self-monitoring of signs and symptoms and when to re-seek medical attention should be provided to all patients.', 'context': 'Clear instructions on self-monitoring of signs and symptoms and when to re-seek medical attention should be given to all patients with LRTI who are discharged from the ED without antibiotics (good practice statement for use, expert opinion)'}
{'question': 'Should antibiotics be prescribed to patients presenting to the ED with non-severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and low suspicion of bacterial pneumonia?', 'answer': 'No, based on a weak recommendation for use and very low certainty of evidence.', 'context': 'We suggest withholding antibiotics in patients presenting to the ED with non-severe AECOPD and low suspicion of bacterial pneumonia (weak recommendation for use, very low certainty of evidence)'}
{'question': 'What should be clearly communicated to all patients with AECOPD who are discharged from the ED without antibiotics?', 'answer': 'Clear instructions on self-monitoring of signs and symptoms and when to re-seek medical attention.', 'context': 'Clear instructions on self-monitoring of signs and symptoms and when to re-seek medical attention should be given to all patients with AECOPD who are discharged from the ED without antibiotics (good practice statement for use, expert opinion)'}
{'question': 'Should antibiotics be withheld from patients presenting to the ED with a provisional diagnosis of cystitis?', 'answer': 'No, due to a weak recommendation against use and moderate certainty of evidence.', 'context': 'We suggest against withholding antibiotics in patients presenting to the ED with a provisional diagnosis of cystitis (weak recommendation against use, moderate certainty of evidence)'}
{'question': 'Should antibiotics be administered to immunocompetent patients presenting to the ED with an uncomplicated diverticulitis?', 'answer': 'Yes, withholding antibiotics in immunocompetent patients presenting to the ED with an uncomplicated diverticulitis is recommended.', 'context': 'We recommend withholding antibiotics in immunocompetent patients presenting to the ED with an uncomplicated diverticulitis (strong recommendation for use, moderate certainty of evidence)'}
{'question': 'What guidelines should be followed by healthcare providers when discharging patients with uncomplicated diverticulitis without antibiotics?', 'answer': 'Clear instructions on self-monitoring of signs and symptoms and when to re-seek medical attention should be given to all patients with uncomplicated diverticulitis who are discharged from the ED without antibiotics.', 'context': 'Clear instructions on self-monitoring of signs and symptom and when to re-seek medical attention should be given to all patients with uncomplicated diverticulitis who are discharged from the ED without antibiotics (good practice statement for use, expert opinion)'}
{'question': 'Do structured culture follow-up programs in adults discharged from the ED with cultures pending improve appropriateness of antibiotic prescription?', 'answer': 'A structured culture follow-up process/program after discharge from the ED is recommended.', 'context': 'We recommend a structured culture follow-up process/program after discharge from the ED (strong recommendation for use, low certainty of evidence).'}{'question': 'What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCEphRE?', 'answer': 'A carbapenem, such as imipenem or meropenem.', 'context': 'For patients with BSI and severe infection due to 3GCephRE, we recommend a carbapenem (imipenem or meropenem) as targeted therapy'}
{'question': 'What antibiotic should be considered for patients with Blistering Plaque Stomatitis and Acute Keratolysis (BSI) due to 3G cephalosporins without septic shock?', 'answer': 'Ertapenem may be used instead of imipenem or meropenem for patients with BSI due to 3G cephalosporins without septic shock.', 'context': 'For patients with BSI due to 3GCephRE without septic shock,ertapenem instead of imipenem or meropenem may be used'}
{'question': 'What antibiotic regimens are recommended for patients with low-risk, non-severe infections due to 3GCephRE under consideration of antibiotic stewardship?', 'answer': 'Piperacillin-tazobactam, amoxicillin/clavulanic acid or quinolones', 'context': 'For patients with low-risk, non-severe infections due to 3GCephRE, under the consideration of antibiotic stewardship, we suggest piperacillin-tazobactam, amoxicillin/clavulanic acid or quinolones'}
{'question': 'What are the recommended treatments for cUTI in patients without septic shock?', 'answer': 'Aminoglycosides when active in vitro, or intravenous fosfomycin.', 'context': 'For cUTI in patients without septic shock, we conditionally recommend aminoglycosides when active in vitro, for short durations of therapy (conditional recommendation for use, moderate certainty of evidence), or intravenous fosfomycin (strong recommendation for use, high certainty of evidence)'}
{'question': 'What is a recommended stepdown targeted therapy for patients with 3GCephRE infections after stabilization?', 'answer': 'Stepdown targeted therapy following carbapenems, using old b-lactam/b-lactamase inhibitors (BLBLI), quinolones, cotrimoxazole or other antibiotics based on the susceptibility pattern of the isolate.', 'context': 'Among all patients with 3GCephRE infections, stepdown targeted therapy following carbapenems once patients are stabilized, using old b-lactam/b-lactamase inhibitors (BLBLI), quinolones, cotrimoxazole or other antibiotics based on the susceptibility pattern of the isolate, is good clinical practice (good practice statement).'}
{'question': 'Is tigecycline recommended for infections caused by 3GCEPHER?', 'answer': 'No, we do not recommend tigecycline for infections caused by 3GCephRE (strong recommendation against use, very low certainty of evidence).', 'context': 'We do not recommend tigecycline for infections caused by 3GCephRE (strong recommendation against use, very low certainty of evidence).'}
{'question': 'What is good clinical practice when it comes to using reserve antibiotics for patients with 3GCephRE infections?', 'answer': 'Avoiding the use of reserve antibiotics for infections caused by 3GCephRE due to antibiotic stewardship considerations.', 'context': 'Among all patients with 3GCephRE infections, the new BLBLI are reserve antibiotics for extensively resistant bacteria and therefore, we consider it good clinical practice to avoid their use for infections caused by 3GCephRE, due to antibiotic stewardship considerations (good practice statement)'}
{'question': 'Should cephamycins (e.g. cefoxitin, cefmetazole, flomoxef) and cefepime be used for 3GCephRE infections?', 'answer': 'No, we suggest that they should not be used.', 'context': 'We suggest that cephamycins (e.g. cefoxitin, cefmetazole, flomoxef) and cefepime not be used for 3GCephRE infections'}
{'question': 'What is the recommended treatment for patients with 3GCephRE infections at the time of writing?', 'answer': 'There is insufficient evidence to recommend a specific antibiotic regimen.', 'context': 'For cefoperazone-sulbactam, ampicillin-sulbactam, ticarcillinclavulanic acid, temocillin and mecillinam there is insufficient evidence for the management of patients with 3GCephRE infections at the time of writing and therefore no recommendation can be issued.'}
{'question': 'What antibiotic treatment is recommended for patients with severe infections due to CRE?', 'answer': 'Meropenem-vaborbactam or ceftazidime-avibactam, depending on in vitro susceptibility.', 'context': 'For patients with severe infections due to CRE, we suggest meropenem-vaborbactam or ceftazidime-avibactam if active in vitro (conditional recommendation for use, moderate and low certainty of evidence, respectively).'}
{'question': 'What antibiotic class is conditionally recommended for patients with severe infections due to CRE-carrying metallob-lactamases (MBL) and/or resistant to all other antibiotics?', 'answer': 'Cefiderocol', 'context': 'For patients with severe infections due to CRE-carrying metallob-lactamases (MBL) and/or resistant to all other antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam, we conditionally recommend treatment with cefiderocol (conditional recommendation for use, low certainty of evidence).'}
{'question': 'What antibiotics are recommended for patients with non-severe infections due to CRE under antibiotic stewardship?', 'answer': 'Old antibiotics chosen from among those in vitro active on an individual basis, according to the source of infection', 'context': 'For patients with non-severe infections due to CRE, under the consideration of antibiotic stewardship, we consider the use of an old antibiotic, chosen from among the in vitro active on an individual basis and according to the source of infection, as good clinical practice. For patients with cUTI, we suggest aminoglycosides, including plazomicin, over tigecycline '}
{'question': 'In cases of BSI and HAP/VAP, should tigecycline be used?', 'answer': 'No, tigecycline should not be used for BSI and HAP/VAP.', 'context': 'We suggest that tigecycline not be used for BSI and HAP/VAP; if necessary, in patients with pneumonia, clinicians may use highdose tigecycline'}
{'question': 'What is the current evidence-based recommendation on the use of imipenem-relebactam and fosfomycin monotherapies for CRE treatment?', 'answer': 'There is no evidence to recommend for or against the use of imipenem-relebactam and fosfomycin monotherapies for CRE at the time of writing.', 'context': 'There is no evidence to recommend for or against the use of imipenem-relebactam and fosfomycin monotherapies for CRE at the time of writing.'}
{'question': 'For patients with CRE infections susceptible to and treated with ceftazidime-avibactam, meropenem-vaborbactam or cefiderocol, is combination therapy recommended?', 'answer': 'No, we do not recommend combination therapy.', 'context': 'For patients with CRE infections susceptible to and treated with ceftazidime-avibactam, meropenem-vaborbactam or cefiderocol, we do not recommend combination therapy'}
{'question': 'What antibiotic combination therapy is recommended for patients with severe infections caused by CRE carrying MBL and/or resistant to new antibiotic monotherapies?', 'answer': 'Aztreonam and ceftazidime-avibactam combination therapy', 'context': 'For patients with severe infections caused by CRE carrying MBL and/or resistant to new antibiotic monotherapies, we suggest aztreonam and ceftazidime-avibactam combination therapy'}
{'question': 'What is the recommended treatment approach for patients with severe infections caused by CRE susceptible bacteria, when only polymyxins, aminoglycosides, tigecycline or fosfomycin are available?', 'answer': 'Treatment should involve more than one drug active in vitro.', 'context': 'For patients with severe infections caused by CRE susceptible in vitro only to polymyxins, aminoglycosides, tigecycline or fosfomycin, or in the case of non-availability of new BLBLI, we suggest treatment with more than one drug active in vitro. No recommendation for or against specific combinations can be provided.'}
{'question': 'Can high-dose extended-infusion meropenem be used as part of combination therapy for CRE infections if carbapenem-based combination therapy is avoided?', 'answer': 'High-dose extended-infusion meropenem may be used as part of combination therapy if the new BLBLI are not used, but only when the meropenem MIC is 8 mg/L.', 'context': 'We suggest that clinicians avoid carbapenem-based combination therapy for CRE infections, unless the meropenem MIC is  8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination therapy if the new BLBLI are not used'}
{'question': 'In patients with non-severe infections or among patients with low-risk infections, which of the following is good clinical practice regarding antibiotic selection?', 'answer': 'The use of monotherapy chosen from among the in vitro active old drugs, on an individual basis and according to the source of infection.', 'context': 'In patients with non-severe infections or among patients with low-risk infections, under the consideration of antibiotic stewardship, we consider the use of monotherapy chosen from among the in vitro active old drugs, on an individual basis and according to the source of infection as good clinical practice'}
{'question': 'What antibiotic therapy is recommended for patients with severe infections due to DTR-CRPA?', 'answer': 'Ceftolozane-tazobactam', 'context': 'In patients with severe infections due to DTR-CRPA, we suggest therapy with ceftolozane-tazobactam if active in vitro. Insufficient evidence is available for imipenem-relebactam, cefiderocol and ceftazidime-avibactam at this time.'}
{'question': 'Which antibiotics should be considered for use in non-severe or low-risk CRPA infections with antibiotic stewardship in mind?', 'answer': 'Old antibiotics chosen from among in vitro active antibiotics on an individual basis, according to the source of infection.', 'context': 'In patients with non-severe or low-risk CRPA infections, under the consideration of antibiotic stewardship, we consider it good clinical practice to use the old antibiotics, chosen from among the in vitro active antibiotics on an individual basis and according to the source of infection'}
{'question': 'What is recommended regarding the use of combination therapy with new BLBLI (ceftazidime-avibactam and ceftolozane-tazobactam) or cefiderocol for CRPA infections?', 'answer': 'Lacking evidence, we cannot recommend for or against the use of combination therapy with the new BLBLI (ceftazidime-avibactam and ceftolozane-tazobactam) or cefiderocol for CRPA infections.', 'context': 'Lacking evidence, we cannot recommend for or against the use of combination therapy with the new BLBLI (ceftazidime-avibactam and ceftolozane-tazobactam) or cefiderocol for CRPA infections.'}
{'question': 'When treating severe infections caused by CRPA, which combination of drugs should be used if two in vitro active drugs are to be chosen?', 'answer': 'Polymyxins, aminoglycosides, or fosfomycin.', 'context': 'When treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin, we suggest treatment with two in vitro active drugs. No recommendation for or against specific combinations can be provided.'}
{'question': 'In patients with non-severe infections or low-risk CRPA infections, what is good clinical practice regarding antibiotic choice?', 'answer': 'Using monotherapy chosen from among drugs active in vitro, on an individual basis and according to the source of infection.', 'context': 'In patients with non-severe infections or low-risk CRPA infections, under the consideration of antibiotic stewardship, we consider it good clinical practice to use monotherapy chosen from among the drugs active in vitro, on an individual basis and according to the source of infection'}
{'question': 'What antimicrobial regimen is recommended for patients with CRAB susceptible to sulbactam and HAP/VAP?', 'answer': 'Ampicillin-sulbactam', 'context': 'For patients with CRAB susceptible to sulbactam and HAP/VAP, we suggest ampicillin-sulbactam'}
{'question': 'What antibiotics can be used for patients with CRAB resistant to sulbactam?', 'answer': 'A polymyxin or high-dose tigecycline', 'context': 'For patients with CRAB resistant to sulbactam, a polymyxin or high-dose tigecycline can be used if active in vitro. Lacking evidence, we cannot recommend on the preferred antibiotic.'}
{'question': 'Is cefiderocol recommended for treating infections caused by carbapenem-resistant, multi-drug resistant (CRAB) bacteria?', 'answer': 'No, we conditionally recommend against cefiderocol for this purpose.', 'context': 'We conditionally recommend against cefiderocol for the treatment of infections caused by CRAB'}
{'question': 'For patients with CRAB infections, what antibiotic regimens are not recommended?', 'answer': 'Polymyxin-meropenem combination therapy and polymyxin-rifampin combination therapy', 'context': 'For all patients with CRAB infections, we do not recommend polymyxin-meropenem combination therapy or polymyxin-rifampin combination therapy'}
{'question': 'What is the recommended antibiotic therapy for patients with severe and high-risk CRAB infections?', 'answer': 'Combination therapy including two in vitro active antibiotics, among the available antibiotics (polymyxin, aminoglycoside, tigecycline, sulbactam combinations)', 'context': 'For patients with severe and high-risk CRAB infections, we suggest combination therapy including two in vitro active antibiotics among the available antibiotics (polymyxin, aminoglycoside, tigecycline, sulbactam combinations)'}
{'question': 'For patients with CRAB infections, what is considered good clinical practice when a meropenem MIC is less than 8mg/L?', 'answer': 'Carbapenem combination therapy using high-dose extended-infusion carbapenem dosing.', 'context': 'For patients with CRAB infections with a meropenem MIC less than 8mg/L, we consider carbapenem combination therapy, usinghigh-dose extended-infusion carbapenem dosing, as good clinical practice'}
{'question': 'Should rectal screening be performed before colorectal and liver transplant surgery for ESCR-E carriers?', 'answer': 'According to local epidemiology, it is suggested.', 'context': 'We suggest rectal screening to identify ESCR-E carriers before colorectal and liver transplant surgery according to the local epidemiology. It might be a good practice to screen all SOT recipients for ESCR-E before surgery according to the local epidemiology'}
{'question': 'What type of treatment do we recommend for patients colonized with Extracolonic Squamous Cell Carcinoma-Related Esophageal (ESCR-E) undergoing colorectal surgery?', 'answer': 'Targeted PAP (Photodynamic Activation Phototherapy)', 'context': 'We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing colorectal surgery'}
{'question': 'What is the condition for recommending targeted PAP in patients colonized with ESCR-E undergoing liver transplant surgery?', 'answer': 'Patients colonized with ESCR-E undergoing liver transplant surgery', 'context': 'We conditionally recommend targeted PAP in patients colonized with ESCR-E undergoing liver transplant surgery'}
{'question': 'Should targeted PAP be considered for all SOT recipients who are colonized with ESCR-E before surgery?', 'answer': 'Yes', 'context': 'It might be a good practice to consider targeted PAP for all SOT recipients who are colonized with ESCR-E before surgery'}
{'question': 'Should rectal screening be implemented for patients undergoing liver transplant surgery based on local epidemiology?', 'answer': 'Yes, according to the local epidemiology, implementing rectal screening can help identify CRE carriers before liver transplant surgery.', 'context': 'We suggest implementing rectal screening to identify CRE carriers before liver transplant surgery according to the local epidemiology'}
{'question': 'Should targeted PAP be recommended for patients who are colonized with CRE before surgery?', 'answer': 'No recommendation can be issued due to insufficient evidence.', 'context': 'There is insufficient evidence for or against targeted PAP for patients who are colonized with CRE before surgery at the time of writing and therefore no recommendation can be issued.'}
{'question': 'Should rectal screening be implemented before liver transplant surgery based on local epidemiology?', 'answer': 'Yes, we conditionally recommend implementing rectal screening to identify CRAB carriers.', 'context': 'We conditionally recommend implementing rectal screening to identify CRAB carriers before liver transplant surgery according to the local epidemiology'}
{'question': 'Should screening for CRAB be performed on all Solid Organ Transplant (SOT) recipients according to local epidemiology before surgery?', 'answer': 'Yes, it might be a good practice.', 'context': 'It might be a good practice to screen, according to the local epidemiology, all SOT recipients for CRAB before surgery'}
{'question': 'Should PAP be adapted in patients colonized with CRE before surgery?', answer: 'There is insufficient evidence for or against targeted PAP for patients who are colonized with CRE before surgery at the time of writing and therefore no recommendation can be issued.', 'context': 'There is insufficient evidence for or against targeted PAP for patients who are colonized with CRE before surgery at the time of writing and therefore no recommendation can be issued.'}
{'question': 'Should patients be screened for CRAB before surgery?', answer: 'Implementing rectal screening toidentify CRAB carriers before liver transplant surgery according to the local epidemiology is conditionally recommended. It might be a good practice to screen, according to the localepidemiology, all SOT recipients for CRAB before surgery', 'context': 'We conditionally recommend implementing rectal screening toidentify CRAB carriers before liver transplant surgery according tothe local epidemiology. It might be a good practice to screen, according to the localepidemiology, all SOT recipients for CRAB before surgery.'}
{'question': 'Should PAP be adapted in patients colonized with CRAB before surgery?', answer: 'There is insufficient evidence for or against targeted PAP for patients who are colonized with CRAB before surgery at the time of writing and therefore no recommendation can be issued.', 'context': 'There is insufficient evidence for or against targeted PAP for patients who are colonized with CRAB before surgery at the time of writing and therefore no recommendation can be issued.'}
{'question': 'When should we perform the screening for MDR-GNB before surgery?', answer: 'For MDR-GNB screening, cultures performed within 3 weeks prior to surgery may be considered', 'context': 'For MDR-GNB screening, cultures performed within 3 weeks prior to surgery may be considered'}
{'question': 'Should the duration of PAP change in patients colonized with MDR-GNB before surgery?', answer: 'PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB. In transplant surgery other than renal transplant, the extension of PAP duration to 48-72 hours may be considered according to the type of transplant', 'context': 'PAP should be discontinued within 24 hours after surgery in patients colonized with MDR-GNB. In transplant surgery other than renal transplant, the extension of PAP duration to 48-72 hours may be considered according to the type of transplant'}
{'question': 'Should PAP be modified for patients colonized with FQR-E before TRUSPB?', answer: 'The use of targeted PAP for patients who are colonized with FQR-E before TRUSPB is suggested', 'context': 'We suggest the use of targeted PAP for patients who are colonized with FQR-E before TRUSPB'}
{'question': 'Should patients be screened for FQR-E before TRUSPB?', answer: 'Yes, rectal screening to identify FQR-E carriers before TRUSPB is suggested.', 'context': 'We suggest rectal screening to identify FQR-E carriers before TRUSPB.'}
{'question': 'Should screening be performed and PAP modified for patients colonized with MDR-GNB before urologic surgery?', 'answer': 'No, insufficient evidence is available at this time to recommend for or against screening to inform targeted PAP for patients who are colonized with MDR-GNB before urologic surgery.', 'context': 'Insufficient evidence is available at this time to recommend for or against screening to inform targeted PAP for patients who are colonized with MDR-GNB before urologic surgery.'}